Trump Administration Halts Development of Bird Flu Vaccine: What This Means for Public Health

The federal government recently announced it will not pursue a contract with Moderna to develop a vaccine for flu viruses, particularly the H5N1 bird flu that has been affecting dairy cattle in the U.S. The Department of Health and Human Services (HHS) cited concerns about the safety of the mRNA technology involved.

This contract, worth $766 million, aimed to create a preventative solution against potentially pandemic-causing flu strains. Andrew Nixon, HHS Communications Director, said the decision was made after careful consideration. He stressed that mRNA technology is not adequately tested and needs better scrutiny before moving forward.

Dr. Jennifer Nuzzo from Brown University expressed disappointment but wasn’t surprised. She explained that while there are alternatives for making flu vaccines, many are slower and some rely on chicken eggs, which might become scarce during a pandemic. The past influenza pandemic showed that few companies produce these vaccines, which could lead to shortages. “We need a diverse approach to vaccine development,” she advised.

Moderna had reported positive results from a trial with 300 healthy adults and was prepared for more advanced testing. Stéphane Bancel, the CEO of Moderna, emphasized the importance of mRNA technology in responding to emerging health threats.

However, the decision has faced backlash from experts. Dr. Ashish Jha, former COVID-19 response coordinator under President Biden, warned that halting the vaccine development program poses risks to public health. He noted that if H5N1 were to mutate and spread among people, it could lead to severe human illness and deaths.

Michael Osterholm from the University of Minnesota echoed these concerns, stating that this move diminishes the U.S. preparedness for handling influenza pandemics. Meanwhile, the H5N1 virus has spread to various livestock farms, and while there have been limited human cases—70 recorded with only one death in the U.S.—the risk of mutation remains a fear among infectious disease specialists.

As the situation evolves, experts continue to underscore the need for a robust vaccination strategy that includes multiple types of vaccines to ensure readiness for potential pandemics.



Source link